Equity Overview
Price & Market Data
Price: $18.74
Daily Change: +$0.01 / 0.05%
Daily Range: $18.42 - $19.33
Market Cap: $1,105,476,352
Daily Volume: 271,445
Performance Metrics
1 Week: -9.34%
1 Month: -9.60%
3 Months: -8.63%
6 Months: -14.27%
1 Year: -28.96%
YTD: -16.71%
Company Details
Employees: 62
Sector: Health technology
Industry: Biotechnology
Country:
Details
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.